Developing a Nrf2 activator for the treatment of COPD

DESCRIPTION (provided by applicant): Chronic obstructive pulmonary disease (COPD) is a major cause of mortality and morbidity worldwide. In the US alone, the disease afflicts ~13 million people and is the third-leading cause of death. Cigarette smoking isthe primary risk factor for COPD, initiating a persistent and progressive inflammatory immune response. Respiratory infections and pollutants can exacerbate COPD symptoms, often leading to pulmonary tissue injury. Currently, there are no approved medicinesthat can slow or stop the progression of COPD. Symptoms such as coughing and shortness of breath are typically treated using bronchodilators. Despite the key role of inflammation in the pathogenesis of COPD, treatment with anti-inflammatory corticosteroiddrugs provides limited therapeutic benefit. Corticosteroid treatment reduces symptoms in only about 20% of COPD patients without improving survival or slowing disease progression. New treatments that inhibit inflammation and improve corticosteroid re